AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $66.02
  • 50 Day Moving Average: $5023.51
  • 200 Day Moving Average: $4386.43
  • 52-Week Range: £12,650,000 - GBX 3,680
  • Trailing P/E Ratio: 29.33
  • P/E Growth: 0.00
  • Market Cap: $64.93B
  • Outstanding Shares: 1,265,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Ratings, 14 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.23)
Consensus Price Target: GBX 4,926.80

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
9/28/2016Shore CapitalReiterated RatingHoldView Rating Details
9/28/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
9/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
9/21/2016Jefferies GroupReiterated RatingBuyGBX 5,800View Rating Details
9/14/2016Societe GeneraleReiterated RatingBuyGBX 7,000View Rating Details
9/14/2016BNP ParibasDowngradeNeutralGBX 5,200View Rating Details
9/13/2016Liberum CapitalReiterated RatingHoldGBX 5,200View Rating Details
9/8/2016Berenberg BankReiterated RatingBuyGBX 5,550View Rating Details
9/6/2016Goldman Sachs Group Inc.Set Price TargetSellGBX 4,000View Rating Details
9/6/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
8/25/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details
8/19/2016Morgan StanleyBoost Price TargetOverweightGBX 5,000 -> GBX 5,800View Rating Details
8/11/2016HSBCReiterated RatingHoldGBX 4,700View Rating Details
7/29/2016Credit Suisse Group AGReiterated RatingUnderperformGBX 4,000View Rating Details
7/29/2016Sanford C. BernsteinSet Price TargetNeutralGBX 5,168View Rating Details
7/28/2016Bryan, Garnier & CoReiterated RatingBuyView Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
4/25/2016Barclays PLCReiterated RatingEqual WeightGBX 5,000View Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
11/16/2015Kepler Capital MarketsReiterated RatingReduceGBX 3,700View Rating Details
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details
4/9/2015Redburn PartnersUpgradeBuyView Rating Details
11/7/2014Cenkos Securities LtdReiterated RatingHoldView Rating Details
(Data available from 9/28/2014 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $4.08 EPS


Dividend History for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline logoFacebook Founder’s Science Group Hires AstraZeneca Board Member (LON:AZN) - September 28 at 8:33 AM
News IconDrug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) Position of the day (LON:AZN) - September 24 at 9:01 AM
News IconWatch List - AstraZeneca PLC's (AZN) - Hot Stocks Point (LON:AZN) - September 23 at 8:45 AM logoIs this a better healthcare buy than AstraZeneca plc after today’s update? (LON:AZN) - September 23 at 8:45 AM logoPharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO (LON:AZN) - September 23 at 8:45 AM logoAstraZeneca Selects LLamasoft as Supply Chain Design Partner of Choice (LON:AZN) - September 21 at 4:38 PM logoAstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy (LON:AZN) - September 21 at 7:38 AM logo[$$] Opinions split on Witty regime at GSK (LON:AZN) - September 20 at 3:41 PM
News IconHC Stocks Review! Mylan NV (MYL), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (LON:AZN) - September 20 at 9:38 AM logoCiti Research Reevaluates Bristol-Myers, Lowers Price Target - Benzinga (LON:AZN) - September 20 at 9:38 AM logoAstraZeneca : *UBS RAISES ASTRAZENECA PRICE TARGET TO 5480 PENCE - 'BUY' (LON:AZN) - September 19 at 4:37 PM
News IconHigh Market Cap Stock of the Day – AstraZeneca PLC (NYSE:AZN) (LON:AZN) - September 19 at 4:37 PM logoTOP NEWS: AstraZeneca Sees Positive Results In Type-2 Diabetes Trial (LON:AZN) - September 16 at 8:59 AM logoAstraZeneca Diabetes Drug Combination Shows Promise in Study (LON:AZN) - September 16 at 8:59 AM logoAstrazeneca says Forxiga combination beats use of drug alone (LON:AZN) - September 16 at 8:59 AM logoMoody's: EMEA non-financial firms may face cash flow squeeze after UK pension updates in 2016-17 (LON:AZN) - September 14 at 6:46 AM
News IconCitigroup Indicates Potential 18.11% Increase In Shares Of Man Group PLC (LON:AZN) - September 12 at 3:39 PM logoAstraZeneca plc (ADR) (AZN) Shares Have Over 20% Upside Potential, Says Analyst (LON:AZN) - September 12 at 3:39 PM logoAstraZeneca plc 20.7% Potential Upside Indicated by Jefferies International - DirectorsTalk Interviews (LON:AZN) - September 12 at 3:39 PM
News IconHC Stocks Review= AstraZeneca plc (AZN), Medtronic PLC (NYSE:MDT) - share market updates (press release) (LON:AZN) - September 9 at 8:30 AM logoAvara Acquires AstraZeneca Plc (NYSE:AZN) UK Manufacturing Plant - Market Exclusive (LON:AZN) - September 8 at 3:38 PM logoRedx Pharma welcomes former AstraZeneca executive (LON:AZN) - September 8 at 9:18 AM logo[$$] Moderna Therapeutics Raises $474M, Secures Grant for Zika Vaccine (LON:AZN) - September 7 at 11:44 AM logoThe Morning Risk Report: AstraZeneca's Avoids Bribery Charges (LON:AZN) - September 6 at 8:31 AM logoAstraZeneca: Benralizumab Phase III Trials For Severe Asthma Meet Main Goals (LON:AZN) - September 5 at 8:33 AM logoAstraZeneca seeks edge over rivals in severe asthma treatment (LON:AZN) - September 5 at 8:33 AM logoAstraZeneca’s Asthma Injection Helps Lungs in Advanced Tests (LON:AZN) - September 5 at 8:33 AM
News IconStock's Traders Recap- AstraZeneca PLC's (AZN) - Hot Stocks Point (LON:AZN) - September 1 at 3:41 PM logo[$$] Pfizer Buys Part of AstraZeneca's Antibiotics Business (LON:AZN) - August 24 at 11:55 AM logoETF’s with exposure to AstraZeneca Plc : August 24, 2016 (LON:AZN) - August 24 at 11:55 AM logoAstraZeneca plc (ADR)'s (AZN) Symbicort Gets New Life - TCC (LON:AZN) - August 23 at 3:43 PM logoIs AstraZeneca’s Valuation Improving Compared to Peers? (LON:AZN) - August 23 at 3:43 PM logoAstraZeneca Plc :AZN-GB: Earnings Analysis: Q2, 2016 By the Numbers : August 23, 2016 (LON:AZN) - August 23 at 6:13 AM logoLilly, AstraZeneca Alzheimer's drug fast tracked (LON:AZN) - August 22 at 8:31 AM logoLilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease (LON:AZN) - August 22 at 8:31 AM logo[$$] Eli Lilly, AstraZeneca Progress With Alzheimer's Drug (LON:AZN) - August 22 at 8:31 AM logo[$$] Pharmaceuticals: Staying power (LON:AZN) - August 21 at 3:39 PM logo[$$] The Profit and Peril of Cancer Drugs (LON:AZN) - August 19 at 4:23 PM logo3 Reasons Inovio Pharmaceuticals Inc. Stock Could Rise (LON:AZN) - August 19 at 12:04 PM logoAstraZeneca (AZN) Making New Innovation for COPD Patients (LON:AZN) - August 17 at 11:55 AM logoAstraZeneca plc (ADR) (AZN) Got Breakthrough In The UK Market - TCC (LON:AZN) - August 15 at 3:50 PM logoFTSE 100 struggles to stay on winning track (LON:AZN) - August 15 at 10:55 AM logoThese FTSE 100 stars have exploded in Q3! And they’re not finished yet (LON:AZN) - August 15 at 10:55 AM logoWill AstraZeneca plc (AZN) Survive Crestor Loss? - The Country Caller - TCC (LON:AZN) - August 13 at 3:42 PM logoAstrazeneca PLC (AZN) Shares are Up 0.41% - Trade Calls (LON:AZN) - August 10 at 8:29 AM logoAstraZeneca inhibitor trial fails to meet endpoint (LON:AZN) - August 9 at 4:48 PM
News IconUnsuccessful and disappointing clinical trials for AstraZeneca's lung cancer drug (LON:AZN) - August 9 at 4:48 PM logoCurrent Analysts Rating Update: Astrazeneca PLC (NYSE:AZN) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates (LON:AZN) - August 9 at 12:34 PM
News IconIs AstraZeneca PLC (NYSE:AZN), a large market cap stock a smart buy? (LON:AZN) - August 8 at 3:45 PM logoAstraZeneca plc (ADR) (AZN): Double Success in Oncology Portfolio Could Prove To Be Highly Lucrative (LON:AZN) - August 8 at 3:45 PM


Last Updated on 9/28/2016 by Staff